LGD-4033 has a single well-known phase I safety and tolerability study in healthy men plus a scattering of case reports. It suppresses endogenous testosterone dose-dependently, and published cases link it to drug-induced liver injury.
Key points
- Phase I dosing (0.1–1 mg/day, 21 days) produced dose-dependent lean mass increase and testosterone suppression.
- Recreational doses commonly discussed online exceed studied doses by several-fold.
- Case reports of hepatotoxicity and one report of drug-induced cholestasis are published.
What the literature shows
The phase I trial reported that LGD-4033 was tolerated over three weeks with dose-proportional suppression of total testosterone and sex hormone binding globulin, and no serious adverse events at the doses studied.
Case reports describe jaundice and markedly raised liver enzymes in young men taking LGD-4033 obtained online, resolving over weeks to months after cessation.
Anti-doping analytical literature documents LGD-4033 detection in supplements not declaring it, indicating contamination risk beyond deliberate use.
What remains unknown
- No trials beyond short-duration phase I in healthy volunteers.
- No dose-response safety data at the ranges used recreationally.
- Hepatic risk factors that predispose to injury are not identified.
Safety and monitoring implications
- Baseline and follow-up liver function and lipid testing are the minimum sensible monitoring if use is occurring.
- Suppression should be expected, not treated as unlikely; post-use hormonal recovery may require clinical input.
- Stacking with other 17-alpha-alkylated or hepatically-stressing compounds compounds the documented risk.
Cited literature
- 1.Basaria S, Collins L, Dillon EL, et al. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral selective androgen receptor modulator, in healthy young men. The Journals of Gerontology: Series A. Find on PubMed
- 2.Barbara M, Dhingra S, Mindikoglu AL. (2020). Ligandrol (LGD-4033)-induced liver injury. ACG Case Reports Journal. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Aggregated community threads
MixedFrequently described as the most 'noticeable' SARM for mass, with correspondingly stronger reports of lethargy, low mood and libido loss during and after use.
Buying Ligandrol / LGD-4033 in Australia: what to check first
APEDRA does not sell Ligandrol / LGD-4033 or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.